Gynecologic Oncology | Interview with Joyce Liu, MD, MPH

published 3 months ago by Dr Neil Love

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Liu on the following topics: Molecular profiling and genetic counseling for patients with newly diagnosed OC (00:00) FDA approval and optimal use of niraparib or olaparib/bevacizumab as front-line maintenance therapy for patients with advanced OC (6:17) Perspective on the benefit with bevacizumab and a PARP inhibitor for patients with OC (9:51) CME information and select publications

more episodes from Research To Practice | Oncology Videos